Amarin And Neopharm Israel Have Entered Into An Exclusive Marketing And Commercialization Agreement For Vazkepa (Icosapent Ethyl) In The State Of Israel, Gaza, The West Bank, And The Territories Of The Palestinian Authority
Portfolio Pulse from Benzinga Newsdesk
Amarin Corporation (AMRN) has entered into an exclusive marketing and commercialization agreement with Neopharm Israel for Vazkepa (Icosapent Ethyl) in Israel, Gaza, the West Bank, and the territories of the Palestinian Authority.
August 08, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amarin's new partnership with Neopharm Israel for the marketing and commercialization of Vazkepa could potentially increase its market reach and revenues.
The exclusive marketing and commercialization agreement with Neopharm Israel allows Amarin to expand its market reach for Vazkepa into Israel and the Palestinian territories. This could potentially lead to increased sales and revenues for the company, positively impacting its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100